Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Azeliragon · TTP-488

Small molecule · Antagonist of RAGE (AGER)

Phase 2 Most advanced trial
1 Registered trials

What is Azeliragon?

Azeliragon is an orally bioavailable inhibitor of RAGE (receptor for advanced glycation end-products) being studied in glioblastoma. It prevents RAGE ligand binding and RAGE-mediated signaling, potentially inhibiting tumor cell proliferation and inducing apoptosis in cancers with overactivated RAGE pathway.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TTP-488
Drug type
Small molecule
Targets
RAGE (AGER)
Mechanism
Antagonist of RAGE (AGER)
Pathways
RAGE-mediated signaling, apoptosis
Therapy area
Oncology
In trials of
MEDP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
LPU25F15UQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05986851 Phase 2 Glioblastoma Active not recruiting MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Other drugs acting on AGER

ARO-RAGE Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.